GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regeneron Pharmaceuticals Inc (LTS:0R2M) » Definitions » Cash Flow from Others

Regeneron Pharmaceuticals (LTS:0R2M) Cash Flow from Others : $-160 Mil (TTM As of Jun. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Regeneron Pharmaceuticals Cash Flow from Others?

Regeneron Pharmaceuticals's cash flow from others for the three months ended in Jun. 2024 was $-396 Mil. Its cash flow from others for the trailing twelve months (TTM) ended in Jun. 2024 was $-160 Mil.


Regeneron Pharmaceuticals Cash Flow from Others Historical Data

The historical data trend for Regeneron Pharmaceuticals's Cash Flow from Others can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regeneron Pharmaceuticals Cash Flow from Others Chart

Regeneron Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Others
Get a 7-Day Free Trial Premium Member Only Premium Member Only -29.30 -135.00 181.70 599.80 266.30

Regeneron Pharmaceuticals Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Cash Flow from Others Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 39.50 115.20 -75.60 196.20 -395.60

Regeneron Pharmaceuticals Cash Flow from Others Calculation

Cash Flow from Others for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-160 Mil.

Regeneron Pharmaceuticals Cash Flow from Others Related Terms

Thank you for viewing the detailed overview of Regeneron Pharmaceuticals's Cash Flow from Others provided by GuruFocus.com. Please click on the following links to see related term pages.


Regeneron Pharmaceuticals Business Description

Address
777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).

Regeneron Pharmaceuticals Headlines

No Headlines